What should be done if the blood concentration of venetoclax does not reach the target?

Venetoclax is a highly targeted BCL-2 inhibitor that exerts anti-tumor effects by inducing apoptosis in tumor cells. The therapeutic effect of the drug depends largely on achieving effective blood concentrations in the body. If the blood drug concentration in the patient's body does not reach the target, it may not only lead to a weakening of the efficacy, but may also induce the risk of disease progression or drug resistance. In actual clinical practice, there are many reasons for insufficient blood drug concentration, which require multi-faceted investigation and intervention.

One of the most common problems is drug interactions with other drugs. Venetoclax is a substrate of theCYP3A enzyme system. If combined with strong CYP3A inhibitors or inducers, its metabolism rate can be significantly affected, resulting in low or high blood concentrations. Therefore, once it is found that the blood drug concentration is not up to standard, the first thing to do is to check whether the recent combined use of drugs that may affect its metabolism should be investigated, and timely adjustments or alternative treatment options should be made.

In addition, the patient's gastrointestinal absorption status is also a key factor affecting blood drug concentration. Venekra needs to be taken with food to increase bioavailability. If the drug is not fully absorbed on an empty stomach or due to problems such as nausea and vomiting, it will also lead to a decrease in blood concentration. At this time, eating habits and medication methods should be evaluated under the guidance of a doctor, and dose compensation or delayed dose adjustment should be made as appropriate.

If it is clear that the blood drug concentration is low, and the patient tolerates it well and does not experience serious side effects, the doctor may consider gradually increasing the dose to make up for the lack of efficacy. However, such adjustments must be made under close monitoring, especially with regard to the risk of tumor lysis syndrome. Some hospitals can accurately determine drug levels in the body through blood drug concentration monitoring (TDM) to guide individualized adjustments.

Reference materials:https://www.venclexta.com/